GlassScriptPhysician profile
Pamela A Penner
NPI 1679550040
$6,844.32
in general payments reported to CMS, 2019-2025
38 companies · $732 in 2025
The $732 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $634 · 2020: $762 · 2021: $1,252 · 2022: $1,338 · 2023: $1,200 · 2024: $926 · 2025: $732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,858.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,857.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,015.29 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $803.24 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Novo Nordisk INC | $792.06 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $706.49 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $432.22 | 2019-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $302.59 | 2019-2024 | Trintellix |
| Amgen INC. | $242.29 | 2019-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $232.34 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Pfizer INC. | $216.21 | 2020-2025 | |
| Galderma Laboratories, L.P. | $211.29 | 2022-2025 | Dysport |
| Bayer Healthcare Pharmaceuticals INC. | $202.19 | 2022-2025 | |
| Glaxosmithkline, LLC. | $184.44 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Sanofi-Aventis U.S. LLC | $168.42 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $144.10 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $131.79 | 2019-2023 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Penner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.